Literature DB >> 16042310

Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease.

Sarah B Domnitz1, Elissa M Robbins, Alex W Hoang, Monica Garcia-Alloza, Bradley T Hyman, G William Rebeck, Steven M Greenberg, Brian J Bacskai, Matthew P Frosch.   

Abstract

Cerebral amyloid angiopathy (CAA), the deposition of beta-amyloid (Abeta3) in cerebral vessels, has been implicated as a common cause of hemorrhagic stroke and other forms of vascular disease. CAA is also a frequent concomitant of Alzheimer disease (AD). While the longterm consequences of CAA are well recognized from clinical and pathologic studies, numerous questions remain unanswered regarding the progression of the disease. Examination of CAA in traditional histologic sections does not easily allow for characterization of CAA, particularly in leptomeningeal vessels. In order to approach this topic, we used low magnification imaging of intact, postmortem brains from transgenic mouse models of AD-like pathology to define the spatial and temporal characteristics of CAA in leptomeningeal vessels. Imaging of brains from 10- to 26-month-old animals demonstrated a stereotypical pattern to the development of CAA, with vessels over the dorsal surface of the brain showing an anterior-to-posterior and large-to-small vessel gradient of involvement. High magnification imaging revealed that CAA deposition began with a banding pattern determined by the organization of the vascular smooth muscle cells. Further analysis of the pattern of amyloid deposits showed shrinkage and disappearance of the gaps between clusters of amyloid bands, gradually reaching a confluent pattern. These data led to a classification system to describe the severity of CAA deposition and demonstrate the potential of using intact brains to generate maps defining the progression and kinetics of CAA. This approach should lead to more informed analysis of the consequences of evolving therapeutic options for AD on this related form of vascular pathology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16042310     DOI: 10.1097/01.jnen.0000171644.00180.fc

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  29 in total

Review 1.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

Review 2.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

Review 3.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.

Authors:  Reisa A Sperling; Clifford R Jack; Sandra E Black; Matthew P Frosch; Steven M Greenberg; Bradley T Hyman; Philip Scheltens; Maria C Carrillo; William Thies; Martin M Bednar; Ronald S Black; H Robert Brashear; Michael Grundman; Eric R Siemers; Howard H Feldman; Rachel J Schindler
Journal:  Alzheimers Dement       Date:  2011-07       Impact factor: 21.566

4.  Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice.

Authors:  Julia L Gregory; Claudia M Prada; Sara J Fine; Monica Garcia-Alloza; Rebecca A Betensky; Michal Arbel-Ornath; Steven M Greenberg; Brian J Bacskai; Matthew P Frosch
Journal:  J Neuropathol Exp Neurol       Date:  2012-11       Impact factor: 3.685

Review 5.  Multiphoton in vivo imaging of amyloid in animal models of Alzheimer's disease.

Authors:  Jinghui Dong; Raquel Revilla-Sanchez; Stephen Moss; Philip G Haydon
Journal:  Neuropharmacology       Date:  2010-04-14       Impact factor: 5.250

6.  Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study.

Authors:  Melita Salkovic-Petrisic; Jelena Osmanovic-Barilar; Martina K Brückner; Siegfried Hoyer; Thomas Arendt; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2011-04-30       Impact factor: 3.575

Review 7.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

8.  Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease.

Authors:  Ian F Kimbrough; Stefanie Robel; Erik D Roberson; Harald Sontheimer
Journal:  Brain       Date:  2015-11-23       Impact factor: 13.501

9.  Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice.

Authors:  Monica Garcia-Alloza; Claudia Prada; Carli Lattarulo; Sara Fine; Laura A Borrelli; Rebecca Betensky; Steven M Greenberg; Matthew P Frosch; Brian J Bacskai
Journal:  J Neurochem       Date:  2009-04-08       Impact factor: 5.372

10.  Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease.

Authors:  Roy O Weller; Stephen D Preston; Malavika Subash; Roxana O Carare
Journal:  Alzheimers Res Ther       Date:  2009-10-12       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.